$PFE Company News
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. Today - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to ‘clear skies’ territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
Newscast: Stocks take a spill to start the week 4:26 p.m. March 3, 2014 - MarketWatch
Pfizer aims to sell over-the-counter version of Lipitor 8:13 a.m. March 3, 2014 - Peter Loftus
Newscast: Pfizer moves to make Lipitor OTC 7:39 a.m. March 3, 2014 - MarketWatch
Best stocks for legalized marijuana 1:37 p.m. Feb. 27, 2014 - blogs.marketwatch.com
Pfizer pneumonia vaccine study meets objectives 7:45 a.m. Feb. 24, 2014 - MarketWatch.com
You'd have to be a dope to buy marijuana stocks 1:36 p.m. Feb. 13, 2014 - blogs.marketwatch.com
Australia regulator takes action against Pfizer 11:03 p.m. Feb. 12, 2014 - MarketWatch.com
Pfizer's Bococizumab cuts "bad" cholesterol in mid-stage study 9:32 a.m. Today - Seeking Alpha
The Richest Man In History Reveals His Simple Wealth Generating Secret 8:56 a.m. Today - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:32 a.m. Today - Seeking Alpha
Novartis lung-cancer drug produces response in over half of patients 4:26 a.m. Today - Seeking Alpha
The Only 20 Companies That Matter 8:03 p.m. March 26, 2014 - Seeking Alpha
Positive Data on Halozyme Candidate - Analyst Blog 6:50 p.m. March 26, 2014 - Zacks.com
ARIAD Candidate in Phase II Study - Analyst Blog 6:10 p.m. March 26, 2014 - Zacks.com
10 Healthcare Dogs Prescribe 6% To 16% March Upsides 5:59 p.m. March 26, 2014 - Seeking Alpha
Novartis Drug Shows Promise in Rare Lung Cancer 5:20 p.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Pfizer Gains Slightly on Xalkori Data - Analyst Blog 5:16 p.m. March 26, 2014 - Zacks.com
Which Drugmaker Will Snap Up Merck’s Consumer Health Unit? 4:58 p.m. March 26, 2014 - Wall St. Cheat Sheet
Dow Drops Amid Soft Underlying Durable Goods 4:28 p.m. March 26, 2014 - TheStreet.com
Top Stock Picks From an Index-Crushing Manager 10:50 a.m. March 26, 2014 - Barrons.com
Stock Market News for March 26, 2014 - Market News 10:06 a.m. March 26, 2014 - Zacks.com
Big pharma investing in regenerative medicine 8:33 a.m. March 26, 2014 - Seeking Alpha
Pfizer's Genotropin meets main goal in Phase IIIb study 8:33 a.m. March 26, 2014 - Seeking Alpha
Telecoms Liven Up Short Interest in Big Dividend Stocks 8:15 a.m. March 26, 2014 - 247WallSt.com
J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now 8:15 a.m. March 26, 2014 - 247WallSt.com
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews 2:17 a.m. March 26, 2014 - Zacks.com
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook 2:17 a.m. March 26, 2014 - Zacks.com
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. Today - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. Today - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 8:31 a.m. March 20, 2014 - BusinessWire - BZX
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories 8:00 a.m. March 20, 2014 - PR Newswire - PRF
Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors 4:00 p.m. March 19, 2014 - PR Newswire - PRF
ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence 9:45 a.m. March 19, 2014 - PR Newswire - PRF
Insider Trading Research - Alerts for Microsoft, Oracle, Pfizer, Plug Power, Sirius XM, and Bank of America 8:55 a.m. March 19, 2014 - PR Newswire - PRF
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 8:15 a.m. March 19, 2014 - GlobeNewswire
Pfizer Launches 2013 Integrated Annual Review 10:00 a.m. March 18, 2014 - BusinessWire - BZX
Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce Senior Level Appointments- Analyst Notes on Pfizer, Boston Scientific, WellPoint, Aetna, and Humana 8:00 a.m. March 18, 2014 - PR Newswire - PRF
U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 1:00 p.m. March 14, 2014 - BusinessWire - BZX
Insider Trading Alert - Research Report on Facebook, Intel, Yahoo, Plug Power, FuelCell Energy, and Pfizer 8:55 a.m. March 14, 2014 - PR Newswire - PRF
Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent 2:28 p.m. March 12, 2014 - BusinessWire - BZX
Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014 10:01 a.m. March 12, 2014 - BusinessWire - BZX
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. Today - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to ‘clear skies’ territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
Newscast: Stocks take a spill to start the week 4:26 p.m. March 3, 2014 - MarketWatch
Pfizer aims to sell over-the-counter version of Lipitor 8:13 a.m. March 3, 2014 - Peter Loftus
Newscast: Pfizer moves to make Lipitor OTC 7:39 a.m. March 3, 2014 - MarketWatch
Best stocks for legalized marijuana 1:37 p.m. Feb. 27, 2014 - blogs.marketwatch.com
Pfizer pneumonia vaccine study meets objectives 7:45 a.m. Feb. 24, 2014 - MarketWatch.com
You'd have to be a dope to buy marijuana stocks 1:36 p.m. Feb. 13, 2014 - blogs.marketwatch.com
Australia regulator takes action against Pfizer 11:03 p.m. Feb. 12, 2014 - MarketWatch.com
Pfizer's Bococizumab cuts "bad" cholesterol in mid-stage study 9:32 a.m. Today - Seeking Alpha
The Richest Man In History Reveals His Simple Wealth Generating Secret 8:56 a.m. Today - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:32 a.m. Today - Seeking Alpha
Novartis lung-cancer drug produces response in over half of patients 4:26 a.m. Today - Seeking Alpha
The Only 20 Companies That Matter 8:03 p.m. March 26, 2014 - Seeking Alpha
Positive Data on Halozyme Candidate - Analyst Blog 6:50 p.m. March 26, 2014 - Zacks.com
ARIAD Candidate in Phase II Study - Analyst Blog 6:10 p.m. March 26, 2014 - Zacks.com
10 Healthcare Dogs Prescribe 6% To 16% March Upsides 5:59 p.m. March 26, 2014 - Seeking Alpha
Novartis Drug Shows Promise in Rare Lung Cancer 5:20 p.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Pfizer Gains Slightly on Xalkori Data - Analyst Blog 5:16 p.m. March 26, 2014 - Zacks.com
Which Drugmaker Will Snap Up Merck’s Consumer Health Unit? 4:58 p.m. March 26, 2014 - Wall St. Cheat Sheet
Dow Drops Amid Soft Underlying Durable Goods 4:28 p.m. March 26, 2014 - TheStreet.com
Top Stock Picks From an Index-Crushing Manager 10:50 a.m. March 26, 2014 - Barrons.com
Stock Market News for March 26, 2014 - Market News 10:06 a.m. March 26, 2014 - Zacks.com
Big pharma investing in regenerative medicine 8:33 a.m. March 26, 2014 - Seeking Alpha
Pfizer's Genotropin meets main goal in Phase IIIb study 8:33 a.m. March 26, 2014 - Seeking Alpha
Telecoms Liven Up Short Interest in Big Dividend Stocks 8:15 a.m. March 26, 2014 - 247WallSt.com
J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now 8:15 a.m. March 26, 2014 - 247WallSt.com
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews 2:17 a.m. March 26, 2014 - Zacks.com
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook 2:17 a.m. March 26, 2014 - Zacks.com
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. Today - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. Today - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 8:31 a.m. March 20, 2014 - BusinessWire - BZX
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories 8:00 a.m. March 20, 2014 - PR Newswire - PRF
Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors 4:00 p.m. March 19, 2014 - PR Newswire - PRF
ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence 9:45 a.m. March 19, 2014 - PR Newswire - PRF
Insider Trading Research - Alerts for Microsoft, Oracle, Pfizer, Plug Power, Sirius XM, and Bank of America 8:55 a.m. March 19, 2014 - PR Newswire - PRF
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 8:15 a.m. March 19, 2014 - GlobeNewswire
Pfizer Launches 2013 Integrated Annual Review 10:00 a.m. March 18, 2014 - BusinessWire - BZX
Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce Senior Level Appointments- Analyst Notes on Pfizer, Boston Scientific, WellPoint, Aetna, and Humana 8:00 a.m. March 18, 2014 - PR Newswire - PRF
U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 1:00 p.m. March 14, 2014 - BusinessWire - BZX
Insider Trading Alert - Research Report on Facebook, Intel, Yahoo, Plug Power, FuelCell Energy, and Pfizer 8:55 a.m. March 14, 2014 - PR Newswire - PRF
Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent 2:28 p.m. March 12, 2014 - BusinessWire - BZX
Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014 10:01 a.m. March 12, 2014 - BusinessWire - BZX
